Shanghai Ruijin Hospital North   Report issue

Academic/Hospital Phase 2 Phase 3 Phase 4
Founded: Shanghai China (1907)

Organization Overview

First Clinical Trial
2012
NCT01992198
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

BIRENDRA KUMAR SAH | CHENNAN | Erzhen Chen | Junmin Li | Shanghai Ruijing Hospital | Shanghai Ruijin Hospital North

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Glomerulonephritis, IGA (Phase 4)

Kidney Diseases (Phase 4)

Leukemia (Phase 3)

Leukemia, Myelogenous, Chronic, BCR-ABL Positive (Phase 3)

Leukemia, Myeloid (Phase 3)

Leukemia, Myeloid, Acute (Phase 2)

Myelodysplastic Syndromes (Phase 3)

Pancreatitis (Phase 4)

Pancreatitis, Acute Necrotizing (Phase 4)

Preleukemia (Phase 3)

Purpura (Phase 2)

Purpura, Thrombocytopenic (Phase 2)

Purpura, Thrombotic Thrombocytopenic (Phase 2)

Syndrome (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 7
  • # of Trial APIs: 17